Titre:
  • Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Auteur:Leleu, Xavier; Attal, Michel; Arnulf, Bertrand; Moreau, Philippe; Traulle, Catherine; Marit, Gerald; Mathiot, Claire; Petillon, Marie Odile; Macro, Margaret; Roussel, Murielle; Pegourie, Brigitte; Kolb, Brigitte; Stoppa, Anne Marie; Hennache, Bernadette; Bréchignac, Sabine; Meuleman, Nathalie; Thielemans, Beatrice; Garderet, Laurent; Royer, Bruno; Hulin, Cyrille; Benboubker, Lotfi; Decaux, Olivier; Escoffre-Barbe, M.; Michallet, Mauricette; Caillot, Denis; Fermand, Jean-Paul; Avet-Loiseau, H; Facon, Thierry; Intergroupe Francophone du Myélome,
Informations sur la publication:Blood, 121, 11, page (1968-1975)
Statut de publication:Publié, 2013-03
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Boronic Acids -- administration & dosage
Dexamethasone -- administration & dosage -- adverse effects
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm -- drug effects
France
Humans
Medical Oncology -- organization & administration
Middle Aged
Multiple Myeloma -- drug therapy
Pyrazines -- administration & dosage
Societies, Medical
Thalidomide -- administration & dosage -- adverse effects -- analogs & derivatives
Treatment Failure
Treatment Outcome
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0006-4971
info:doi/10.1182/blood-2012-09-452375
info:pii/blood-2012-09-452375
info:scp/84877622448
info:pmid/23319574